We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Pneumocystis jirovecii Genome Exemplifies Obligate Parasite Infecting only Humans

By LabMedica International staff writers
Posted on 07 Jan 2013
Genomics researchers using a novel in silico selection technique have sequenced the genome of the fungus Pneumocystis jirovecii from a sample obtained from the lung of a single patient.

Pneumocystis pneumonia (PCP) or pneumocystosis is a form of pneumonia caused by the yeast-like fungus P. More...
jirovecii. It is an opportunistic infection that occurs most frequently in individuals with diminished immune systems such as AIDS victims or organ transplant recipients. The pathogen is specific to humans and has not been shown to infect other animals. Other species of Pneumocystis that parasitize other animals have not been shown to infect humans.

Despite having been discovered more than one hundred years ago, P. jirovecii cannot be grown in culture. Since this method for producing a specimen for gene mapping was unavailable, investigators at the University of Lausanne (Switzerland) turned to a single bronchoalveolar lavage-fluid specimen from a patient.

The investigators concentrated the P. jirovecii cells in the specimen using immunoprecipitation and then amplified copies of the fungal DNA by PCR. This mixture of DNA strands - from the fungus, the patient, and other microbes present in the lungs of the patient - was then sequenced using high throughput technologies.

The major challenge facing the investigators was differentiating sequences of fungal DNA from those belonging to the various contaminants. This task was accomplished, however, and results were published in the December 26, 2012, online edition of the journal mBio. These results revealed that the P. jirovecii genome lacked virulence factors and most amino acid biosynthesis enzymes and presented reduced GC (guanine-cytosine) content and size. Together with epidemiological observations, these features suggested that P. jirovecii was an obligate parasite specialized in the colonization of human lungs, which caused disease only in immune-deficient individuals.

"Recognized first among malnourished infants, P. jirovecii pneumonia became a public issue with the advent of the HIV epidemic," said senior author Dr. Philippe Hauser, professor of molecular mycology at the University of Lausanne. "Today, the disease most commonly affects HIV-infected persons who are unaware of their status as well as solid organ transplant recipients and patients with hemato-oncologic or autoimmune diseases. Since the organism cannot be grown in the lab for study, researchers have long made do with studying P. jirovecii's lab-friendly relatives, species that infect animals and plants, in order to explore the secrets of the human disease. It is obviously better to study [P. jirovecii's] genes rather than those of Pneumocystis species from animal models. The genome has both medical and evolutionary interests for the scientific community."

Related Links:
University of Lausanne


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.